Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland)
Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2539
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland). Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma. 2539
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: